Enhancing CTL responses to melanoma cell vaccines in vivo: Synergistic increases obtained using IFNγ primed and IFNβ treated B7-1 + B16-F10 melanoma cells

Immunology and Cell Biology

Volumn 81, Issue 6, 2003, Pages 459-471

  Dezfouli, Shala ^a   Hatzinisiriou, Irene ^a   Ralph, Stephen J ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Antigen presentation; Costimulation; CTL response; Cytokines; Interferons; Melanoma; Tumour immunity; Vaccination

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CANCER VACCINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL KILLING; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTORS, CELL SURFACE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MURINAE;

EID: 1642546952     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2003.01189.x     Document Type: Article

References (50)

1. Dezfouli S, Hatzinisiriou I, Ralph SJ. Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy. Curr. Pharm. Des. 2004. In press.
2. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumour cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 447-56.
3. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumour surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 1998; 95: 7556-61.
4. Shankaran V, Ikeda H, Bruce AT et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
5. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. IFN increases HLA synthesis in melanoma cells: IFN-resistant and -sensitive cells. Proc. Natl Acad. Sci. USA 1982; 79: 3265-9.
6. Ruiter DJ, Brocker EB, Ferrone S. Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance. J. Immunogenet 1986; 13: 229-34.
7. Johnson DR, Pober JS. HLA class I heavy-chain gene promoter elements mediating synergy between tumour necrosis factor and IFNs. Mol. Cell. Biol. 1994; 14: 1322-32.
8. van den Elsen PJ, Gobin SJ, van Eggermond MC, Peijnenburg A. Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 1998; 48: 208-21.
9. Lonergan M, Dey A, Becker KO, Drew PD, Ozato K. A regulatory element in the beta 2-microglobulin promoter identified by in vivo footprinting. Mol. Cell Biol. 1993; 13: 6629-39.
10. Vraetz T, Ittel TH, van Mackelenbergh MG, Heinrich PC, Sieberth HG, Graeve L. Regulation of beta2-microglobulin expression in different human cell lines by proinflammatory cytokines. Nephrol. Dial. Transplant 1999; 14: 2137-43.
11. Tatsumi T, Takehara T, Katayama K et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997; 25: 1108-14.
12. Tsukada N, Aoki S, Maruyama S, Kishi K, Takahashi M, Aizawa Y. The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by IFN. J. Exp. Clin. Cancer Res. 1997; 16: 171-6.
13. Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induced autoimmune T-cells through the induction of intracellular adhesion molecule-1 and B72. J. Immunol. 1996; 157: 522-8.
14. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J. Mol. Med. 1996; 74: 13-33.
15. Wong LH, Hatzinisiriou I, Devenish RJ, Ralph SJ. IFN-gamma-priming up-regulates ISGF3 components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J. Immunol. 1998; 160: 5475-84.
16. Mizukoshi E, Kaneko S, Yanagi M, Ohno H, Matsushita E, Kobayashi K. Upregulation of type I interferon receptor by IFN-gamma. J. Interferon Cytokine Res. 1999; 19: 1019-23.
17. Nicolson GL. Cancer metastasis. Sci. Am. 1979; 240: 66-76.
18. Celik C, Lewis DA, Goldrosen MH. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res. 1983; 43: 3507-10.
19. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 1993; 90: 3539-43.
20. Itoh T, Storkus WJ, Gorelik E, Lotze MT. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J. Immunol. 1994; 153: 1202-15.
21. Cavallo F, Martin-Fontecha A, Bellone M et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 1995; 25: 1154-62.
22. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 1995; 11: 1415-21.
23. Nishio M, Spielman JM, Lee RK, Nelson DL, Podack ER. CD80 (B7. 1) and CD54 (intracellular adhesion molecule-1) induce target cell susceptibility to promiscuous cytotoxic T-cell lysis. J. Immunol. 1996; 157: 4347-53.
24. Fleischmann CM, Wu TY, Fleischmann WR Jr. B16 melanoma cells exposed in vitro to long-term IFN-α treatment (B16a cells) as activators of tumor immunity in mice. J. Interferon Cytokine Res. 1997; 17: 37-43.
25. Wu TY, Fleischmann WR Jr. Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice. J. Interferon Cytokine Res. 1998; 18: 829-39.
26. Roth AD, Hornicek FJ, Gerstner CG, Kirkwood JM. Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin. Exp. Immunol. 1991; 86: 163-72.
27. Palmer KJ, Harries M, Gore ME, Collins MK. Interferon-alpha (IFN-α) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin. Exp. Immunol. 2000; 119: 412-8.
28. LeMay LG, Kan-Mitchell J, Goedegeburre P, Harel W, Mitchell MS. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T-cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol. Immunother. 1993; 37: 187-94.
29. Kirkin AF, thor Straten P, Zeuthen J. Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T-cell clones that recognize differentiation or progression antigens. Cancer Immunol. Immunother. 1996; 42: 203-12.
30. Cosgrove D, Gray D, Dierich A et al. Mice lacking MHC class II molecules. Cell 1991; 66: 1051-66.
31. Whitehead RH, Little JH. Tissue culture studies on human malignant melanoma. In: McGovern, VJ, Russell, P, eds. Pigment T-cell, Vol. 1. Basel (Switzerland). S. Karger Press 1973; 382-9.
32. Mashko SV, Veiko VP, Lapidus AL et al. TGATG vector: a new expression system for cloned foreign genes in Escherichia coli cells. Gene 1990; 88: 121-6.
33. Hertzog PJ, Emery P, Cheetham BF, Mackay IR, Linnane AW. Interferons in rheumatoid arthritis: alterations in production and response related to disease activity. Clin. Immunol. Immunopathol. 1988; 48: 192-201.
34. Wunderlich J, Shearer G. In vitro assays for mouse lymphocyte function. In: Coligan, JE, Kruisbeek, AM, Margulies, DH, Shevach, EM, Strober, E, eds. Current Protocols in Immunology. New York: Greene Publications, Associates and Wiley-Interscience Press, 1993; 11-14.
35. Tsujimura K, Takahashi T, Iwase S et al. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements. J. Immunol. 1998; 160: 5253-61.
36. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans. Blood 2000; 95: 2352-5.
37. Zhou H, Stuge TB, Miller NW et al. Heterogeneity of channel catfish CTL with respect to target recognition and cytotoxic mechanisms employed. J. Immunol. 2001; 167: 1325-32.
38. Chambers CA, Allison JP. Costimulatory regulation of T-cell function. Curr. Opin. Cell Biol. 1999; 11: 203-10.
39. Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumour rejection requires a CTLA4 ligand provided by the host or expressed on the tumour. Superiority of B7-1 over B7-2 for active tumour immunization. J. Immunol. 1996; 156: 2909-17.
40. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumours in vivo? J. Exp. Med. 1996; 183: 769-76.
41. Hirano N, Takahashi T, Takahashi T et al. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80) -transduced leukemic cells. Hum. Gene Ther. 1997; 8: 1375-84.
42. Delon J, Germain RN. Information transfer at the immunological synapse. Curr. Biol. 2000; 10: R923-33.
43. Lanzavecchia A, Sallusto F. From synapses to immunological memory: the role of sustained T-cell stimulation. Curr. Opin. Immunol. 2000; 12: 92-7.
44. Simon MM, Waring P, Lobigs M et al. Cytototoxic T-cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis. J. Immunol. 2000; 165: 3663-72.
45. Bohm W, Thoma S, Leithuaser F, Moller P, Schirmbeck R, Reimann J. T-cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J. Immunol. 1998; 161: 897-908.
46. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol. Rev. 1999; 170: 85-100.
47. Mitchell MS. Cancer vaccines, a critical review - Part I. Curr. Opin. Invest. Drugs 2002; 3: 140-9.
48. Hsueh EC, Essner R, Foshag LJYeW, Morton DL. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann. Surg. Oncol. 2002; 9: 486-92.
49. Hersey P, Si Z, Smith MJ, Thomas WD. Expression of the costimulatory molecule B7 on melanoma cells. Int. J. Cancer 1994; 58: 527-31.
50. Sturmhoefel K, Lee K, Gray GS et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. 1999; 59: 4964-72.